Biomarker ID | 1773 |
PMID | 30334974 |
Year | 2018 |
Biomarker | tPSA+ hK2+ PCA3+ miR-141 |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Blood |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include (hK2): Galactose metabolism, Fructose and mannose metabolism, Hexose transport, Carbohydrate metabolism, SLC-mediated transmembrane transport |
Experiment | Prostate Cancer Vs Benign prostatic hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | 100 patients were analysed for the study. 43 patients had PCa and 57 had benign prostatic hyperplasia group (BPH) |
Senstivity | NA |
Specificity | Full Dataset: 84.2%; PSA range 4 to 10ng/mL: 89.2% |
AUC | Full Dataset: 0.841, 95% CI: 0.761-0.920); PSA range 4 to 10ng/mL: AUC = 0.853, 95% CI: 0.659-1) |
Accuracy | NA |
Level Of Significance | NA |
Method Used | qRT-PCR |
Clinical | No |
Remarks | tPSA+ hK2+ PCA3+ miR-141 cutoff: 104.45; PSA range 4 to 10ng/mL: 0.494 |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |